MedTrace Logo

Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients

NCT02415179 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2016-04-26

No results posted yet for this study

Summary

The purpose of this study is to investigate the effectiveness of inhaled mometasone/formoterol versus inhaled fluticasone/salmeterol on peripheral airway function in treatment of asthma.

Conditions

Interventions

DRUG

Inhaled Mometasone/formoterol

Inhaled Mometasone/formoterol (100/5 microgram) 2 puffs twice daily via metered dose inhaler for 6 weeks

DRUG

Inhaled Fluticasone/Salmeterol

Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Tananchai Petnak, M.D. · Pulmonary and critical care, Department of Medicine, Ramathibodi Hospital, Mahidol University

  • Theerasuk Kawamatawong, M.D. · Pulmonary and critical care, Department of Medicine, Ramathibodi Hospital, Mahidol University

  • Prapaporn Pornsuriyasak, M.D. · Pulmonary and critical care, Department of Medicine, Ramathibodi Hospital, Mahidol University

  • Viboon Boonsarngsuk, M.D. · Pulmonary and critical care, Department of Medicine, Ramathibodi Hospital, Mahidol University

  • Naparat Amornputtisathaporn, M.D. · Pulmonary and critical care, Department of Medicine, Ramathibodi Hospital, Mahidol University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02415179 on ClinicalTrials.gov